ISSN:
0066-4219
Source:
Annual Reviews Electronic Back Volume Collection 1932-2001ff
Topics:
Medicine
Notes:
Abstract Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1146/annurev.med.53.082901.103853
Permalink
